Starting with a microdose approach and finding the lowest effective dose is one strategy for long-term sustainability
Hypoglycaemia (low blood sugar): If you are also taking insulin or a sulfonylurea (e.g., gliclazide) for diabetes, your risk of hypoglycaemia may be increased
On top of the potential predictive value, antibodies to PTM antigens may have clinical relevance to identifying sub-populations of patients such as patients more or less likely to respond to specific therapies (i.e., DMARDs, biologics)
In the landmark FLOW clinical trial published in the New England Journal of Medicine, Semaglutide (Ozempic) reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease
Although calpain-1 is implicated in cytoskeletal breakdown, its genetic ablation does not alter erythrocyte lifespan, indicating possible compensatory mechanisms (Wieschhaus et al., 2012)
.webp)
